Correction to: Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis (Journal of Neurology, (2021), 268, 7, (2364-2376), 10.1007/s00415-020-09707-5)

Abstract

The authors would like to correct errors in the publication of their original article. The corrected details are given below: On page 2 in the second paragraph, the date of first marketing authorization of galcanezumab needs to be corrected to September 2018. The correct sentence is: “Thus, anti-CGRP monoclonal antibodies are used as the prophylactic treatments for migraine. Galcanezumab was authorized in the USA in September 2018.”.